Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of CLN-081 in EGFR exon 20 insertion-mutant non-small cell lung cancer
2024-516532-97-00Phase 2Authorised
- Sponsor
- Cullinan Pearl
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Cullinan Pearl. Planned start Sep 2024; status: authorised.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-516532-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516532-97-00.